BIOLASE, Inc. Granted Extension by Nasdaq to Regain Compliance with the Stockholders' Equity Continued Listing Requirement Feb 14, 2024 6:30am EST
BIOLASE REPORTS UNAUDITED REVENUE GROWTH FOR FULL YEAR 2023 AND PROVIDES OUTLOOK FOR FULL YEAR 2024 Jan 29, 2024 6:30am EST
BIOLASE ENHANCES EDUCATION OFFERINGS IN 2024 DUE TO INCREASING DEMAND OF DENTAL LASER COURSES THROUGHOUT 2023 Jan 08, 2024 4:05pm EST
BIOLASE, Inc. Announces Pricing of $1.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Dec 06, 2023 1:46pm EST
BIOLASE REPORTS THIRD QUARTER FINANCIAL RESULTS; COMPANY BENEFITTING FROM STRATEGIC ACTIONS TAKEN TO STREAMLINE OPERATIONS AND GAIN GREATER OPERATIONAL EFFICIENCIES Nov 09, 2023 4:05pm EST
Landmark Study Performed by the Independent McGuire Institute Confirms Positive 12 Month Clinical Outcomes for BIOLASE REPAIR® Perio Protocol Nov 08, 2023 6:30am EST
